Similarly, Wang et al. studied the inhibitory effects of dihydroartemisinin on CSCs in human colon cancer cells (HCT116 and SW620), and results showed that dihydroartemisinin treatment could significantly reduce the expression of CSC markers (CD133, CD44, Nanog, c-Myc, and OCT4) by downregulating Akt/mTOR pathway [48]. The gene discussed is AKT1; the disease is malignant colon neoplasm.